ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "PharmAthene, Inc." (PIP) Report Updated: Aug 25, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"PharmAthene, Inc." (PIP)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: ENTA, MDVN, GNVC, GILD

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: C down no change
Last Week: C same upgrade
Two Weeks Ago: D up no change
service keys

"PharmAthene, Inc."© quotemedia

Company Profile

PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine that has completed a Phase IIb clinical trial for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody, which has completed a Phase I clinical trial for the prevention and treatment of anthrax infection; and rBChE (recombinant butyrylcholinesterase) bioscavanger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. The company primarily serves the United States Department of Defense, the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and the National Institute of Health. It has a collaboration agreeemtn with Bristol Myers Squibb, Inc. for the development of Valortim. The company was founded in 2001 and is headquartered in Annapolis, Maryland.

Recent News: "PharmAthene, Inc."